Stockwinners Market Radar for April 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Lennar director buys $247K in common stock - In a regulatory filing, Lennar disclosed that its director Amy Banse bought 1.6K shares of common stock on April 10th in a total transaction size of $247K.

20:07 EDT Cathie Wood's ARK Investment bought 143K shares of Roblox today

19:50 EDT Fluent trading halted, news pending

19:50 EDT Agenus trading halted, news pending

19:28 EDT Provident Financial gets Federal Reserve Board approval in Lakeland merger - Provident Financial (PFS) and Lakeland Bancorp (LBAI) "announced receipt of regulatory approval from the Board of Governors of the Federal Reserve System for Provident and Lakeland to complete their previously announced merger. With this approval, no further regulatory approvals are required to complete the merger."

18:28 EDT Bethesda's 'Fallout 4' getting Xbox Series, PS5 upgrade amid TV show release - Microsoft's (MSFT) Bethesda said that 2015 game "Fallout 4" will be receiving a current-generation console upgrade on April 25. The title, which originally launched for PC, PlayStation 4 (SONY), and Xbox One, will be optimized for Xbox Series X/S and PlayStation 5 for free, with players getting stability improvements and fixes, as well as Performance Mode and Quality mode settings. The Fly notes that the announcement comes amid the release of the "Fallout" TV series on Amazon Prime Video (AMZN). Reference Link

17:53 EDT MongoDB director Merriman sells 2,000 class A shares - In a regulatory filing, MongoDB director Dwight Merriman disclosed the sale of 2,000 class A common shares of the company on April 8 at a price of $365 per share.

17:39 EDT Boeing awarded $111.89M Navy contract - Boeing was awarded a not-to-exceed $111.89M undefinitized, firm-fixed-price order against a previously issued basic ordering agreement. This order provides for the production and delivery of avionics long lead time parts and spares to support the advanced crew station suite inclusive of the low profile engine fuel display, large area display, and low profile head up display; life of type buys for parts that have or will become obsolete; and special test equipment in support of the F/A-18E/F Block III and E/A-18G aircraft for the Navy, Royal Australian Air Force, and the country of Kuwait. Work is expected to be completed in May 2028. FY24 aircraft procurement funds in the amount of $16.15M; FY23 aircraft procurement funds in the amount of $9.46M; and Foreign Military Sales customer funds in the amount of $4.88M, will be obligated at the time of award, none of which will expire at the end of the current fiscal year. Naval Air Systems Command is the contracting activity.

17:33 EDT NuZee granted extension of time to regain compliance with Nasdaq rules - NuZee has been granted an extension of time to regain compliance with Nasdaq until June 14. On April 9, the company received a letter from Nasdaq stating that based on the company's plan submission, Nasdaq has determined to grant the company an extension of time to regain compliance with Nasdaq listing rules until June 14. The company must furnish to the SEC and Nasdaq a publicly available report which, among other things, includes a description of the completed transaction or event that enabled the company to satisfy the stockholders' equity requirement for continued listing. After filing the report, if the company fails to evidence compliance upon filing its periodic report for June 30 or the periodic report for September 30, if Nasdaq determines to provide a further extension, the company may be subject to delisting. The company intends to regain compliance

17:31 EDT OncoCyte, BioRad to partner on global launch of GraftAssure assay - The company states: "Oncocyte (OCX) announced a partnership agreement with Bio-Rad Laboratories (BIO) for the commercialization of its research use only GraftAssure assay, powered by Droplet Digital PCR. The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year. As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead. Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights."

17:18 EDT Jeld-Wen closing two window manufacturing facilities in North America - Jeld-Wen announced actions to simplify its North America windows operations by closing its Vista, California, and Hawkins, Wisconsin, manufacturing facilities. In connection with these site closures, the company expects to incur one-time costs of approximately $45M and generate annual pre-tax income improvements of at least $11M. The Vista, California, site has approximately 110 associates. Multiple market factors have made it prohibitive to competitively sustain the composite windows product line and it will be discontinued. As a result, Jeld-Wen plans to close the Vista composite windows facility. Jeld-Wen expects to incur one-time costs in 2024 of approximately $21M related to the Vista closure and after project completion, recognize an annual pre-tax income improvement of at least $4M. The Hawkins, Wisconsin, site employs approximately 340 associates. Jeld-Wen will consolidate production from Hawkins into its wood windows manufacturing facility in Rantoul, Illinois. One-time costs related to this site consolidation are estimated at approximately $24M, most of which should be incurred in 2024. Annual pre-tax income improvement, after completion of these activities, is expected to be at least $7M.

17:02 EDT Targa Resources increases quarterly dividend to 75c per share - Targa Resources announced that its board of directors has declared an increase to its quarterly cash dividend to 75c per common share, or $3.00 per common share on an annualized basis, for the first quarter of 2024, consistent with previously disclosed expectations. This dividend represents a 50% increase over the common dividend declared with respect to the first quarter of 2023. This cash dividend will be paid May 15 on all outstanding common shares to holders of record as of the close of business on April 30.

17:01 EDT Copa Holdings reports March capacity up 12.3%, traffic up 11.5% - The company states: "For March 2024, Copa Holdings' capacity, or ASMs, increased by 12.3%, while system-wide passenger traffic, or RPMs, also increased by 11.5%, compared to 2023. As a result, the system load factor for the month was 86.5%, 0.7 percentage points lower than in March 2023."

16:47 EDT NYSE to commence delisting proceedings against Leju - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the American Depositary Shares, each representing ten ordinary shares, par value $0.001 per share of Leju Holdings Limited - ticker symbol LEJU - from the NYSE. Trading in the company's ADSs will be suspended immediately. The company is currently below compliance with Section 802.01B of the NYSE Listed Company Manual since the Company has a total market capitalization of less than $50 million over a 30 trading-day period and a stockholders' equity of less than $50 million. NYSE Regulation reached its decision to delist the Company's ADSs pursuant to Section 802.03 of the NYSE Listed Company Manual, because the Company submitted a business plan that did not demonstrate an ability to return to compliance with continued listing standards within 18 months of notice from the Exchange as required by Section 802.03 of the NYSE Listed Company Manual. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the ADSs upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

16:45 EDT First Wave CEO says in process of capital raise, sees share price going up

16:43 EDT Nutanix CFO sells $3.43M in common stock - In a regulatory filing, Nutanix disclosed that its CFO Rukmini Sivaraman sold 53K shares of common stock on April 10th in a total transaction size of $3.43M.

16:35 EDT Top Ships to transfer listing to NYSE from Nasdaq - Top Ship announced that it will transfer the listing of its common shares from Nasdaq to the NYSE. The company expects to commence trading as a NYSE American-listed company at market open on April 24 under its existing ticker symbol, (TOPS). The company's shares will continue to trade on the Nasdaq until the market close on April 23, beginning trading on the NYSE American at market open on the next trading day without interruption or impact to investors. Company investors are not required to take any action.

16:33 EDT PaxMedica provides update on potential PAX-101 NDA submission - PaxMedica announced the completed execution of its three registration/validation batches of PAX-101, an IV formulation of suramin. The company said this achievement is an important milestone to enabling a new drug application, or NDA, submission to the FDA, which is currently planned for Q4 and for the potential commercial availability in the U.S. of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis, or HAT, caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease, if approved by the FDA. The company said reaching this milestone is critical to PaxMedica's journey towards potential FDA approval for PAX-101, currently the accepted standard of treatment outside the United States for the deadliest cause of HAT, according to the CDC. A successful review and approval of the NDA could further qualify the company for a Tropical Disease Priority Review Voucher, or PRV. PaxMedica plans to fund a sustainable global supply chain for PAX-101, and further advance research and clinical trials to address Autism Spectrum Disorder.

16:31 EDT Molina Healthcare wins Michigan Medicaid contract - Molina Healthcare announced that the Michigan Department of Health and Human Services intends to award a Comprehensive Health Care Program contract to Molina's health plan subsidiary, Molina Healthcare of Michigan. Molina confirmed it was awarded the contract in six service regions. The go-live date for Molina Healthcare of Michigan's new Medicaid contract is expected to be October 1, 2024. The next contract is expected to have a duration of five years, with three, one-year optional extensions. Molina Healthcare of Michigan will be one of nine health plans offering health care coverage to Michigan's nearly 2M total Medicaid beneficiaries.

16:22 EDT Nasdaq reports March US equity option volume 248M vs. 300M last year - Nasdaq reported monthly volumes for March 2024, as well as quarterly volumes, estimated revenue capture, number of listings, and index statistics for the quarter ended March 31...

16:17 EDT Brixmor CEO James Taylor Jr. taking temporary medical leave of absense - Brixmor's CEO and President James Taylor Jr. is taking a temporary medical leave of absence, effective April 11, 2024. The Board of Directors appointed Brian Finnegan, SVP, COO, to also serve as interim CEO and President until Taylor's return.

16:06 EDT AAR Corp. extends engine component distribution agreement with Sumitomo - AAR has signed an extension and expansion of its V2500 engine component distribution agreement with Sumitomo Precision Products. Under the agreement, AAR has extended its exclusive agreement to distribute the V2500 pneumatic starter and starter control valve on behalf of SPP for the life of the program. The contract also expands AAR's exclusive distributorship with the addition of all V2500 starter/valve subcomponents.

16:05 EDT Medallion, TriBeam Financial announce Fintech strategic partnership - Medallion Bank (MBNKP) announced it had entered into a definitive agreement with TriBeam Financial to be its finance partner for home solar systems and related products. The Bank is a wholly owned subsidiary of Medallion Financial (MFIN). TriBeam Financial is a fintech company that provides a point-of-sale lending platform for residential solar equipment and home improvement loans in the U.S. through its large network of installers. Donald Poulton, President and Chief Executive Officer of Medallion Bank, stated, "We are pleased to add TriBeam Financial to our strategic partnership program. It has the potential to be our largest partner yet and is a great fit for us since it expands our reach within our home improvement lending segment." Alexi Evriviades, Founder and Chief Executive Officer of TriBeam Financial, stated, "We look forward to our partnership with Medallion Bank, which brings a wealth of expertise in administering home improvement loans through contractors and offers us the best platform to serve consumers through our national base of solar installers." Loan origination activities have started under this agreement.

14:20 EDT Morgan Stanley down 5% after WSJ report on probes of wealth unit

13:42 EDT Kove says won $525M judgment in patent infringement case against AWS - Kove, which calls itself "an innovator in high-performance computing solutions," announced it has prevailed in a $525M patent infringement verdict against Amazon Web Services, or AWS. "In its ruling, the jury found that AWS infringed all three patents at stake in the litigation. The three patents cover breakthrough technology that allow cloud storage to scale unlimitedly," Kove stated. "Yesterday's success highlights the importance of protecting intellectual property rights. By doing so, we create an environment where innovation and creativity can flourish, benefiting not only our company but also our customers and the industry as a whole. We are committed to defending our innovations and leading through our pioneering technology," Kove founder and CEO John Overton added.

13:35 EDT Globe Life trading halted, volatility trading pause

12:21 EDT Volvo to increase North American heavy truck production capacity - The Volvo Group will build a new heavy-duty truck manufacturing plant in Mexico to supplement the Group's U.S. production. The plant will provide additional capacity to support the growth plans of both Volvo Trucks and Mack Trucks in the U.S. and Canadian markets, and support Mack truck sales in Mexico and Latin America. The plant is expected to be operational in 2026. The Mack LVO plant in Pennsylvania and the Volvo NRV plant in Virginia will continue to be the company's main North American heavy truck production sites. The Group has invested more than $73 million over the last five years in LVO expansion and upgrades, and is currently investing an additional $80 million to prepare for future production. The NRV plant is completing a six-year, $400 million dollar expansion/upgrade to prepare for production of the new Volvo VNL model. The new plant will be approximately 1.7 million square feet in size, and will focus on production of heavy-duty conventional vehicles for the Volvo and Mack brands. It will be a complete conventional vehicle assembly facility including cab body-in-white production and paint. Adding production in Mexico will deliver logistical efficiencies for supporting sales to the southwestern/western regions of the U.S., and to Mexico and Latin America. It also provides a mature supply and production ecosystem that will complement the U.S. system and increase the resilience and flexibility of the Group's North American industrial footprint.

12:00 EDT PropertyGuru rises 6.1% - PropertyGuru is up 6.1%, or 23c to $3.99.

12:00 EDT a.k.a. Brands rises 11.4% - a.k.a. Brands is up 11.4%, or $1.13 to $11.00.

12:00 EDT CarMax falls -13.2% - CarMax is down -13.2%, or -$10.48 to $68.82.

11:21 EDT Ted Miller makes statement on appointment of Crown Castle CEO - Ted B. Miller, co-founder and former Executive Chairman and CEO of Crown Castle and his investment vehicle Boots Capital Management, LLC issued a statement regarding Crown Castle's appointment of Steven J. Moskowitz as President and CEO: "Like all Crown Castle shareholders, we are just learning about Mr. Moskowitz's appointment and are reviewing his qualifications to serve as Crown Castle's CEO. We believe this announcement reinforces the critical need for Boots Capital's highly qualified director nominees to join the Crown Castle Board at this critical juncture. The current Board has a decade-long track record of inferior total shareholder returns for Crown Castle. By contrast, our nominees have the direct tower operating experience, deep internal knowledge and understanding of Crown Castle's business and employee base, as well as the capital markets expertise and ability to successfully oversee a thorough review of the fiber business, all of which are critical to ensure Mr. Moskowitz's success and to drive long-term value for all Crown Castle shareholders."

11:12 EDT Wex files trademark infringement lawsuit against HP Inc. - WEX (WEX) has filed a federal lawsuit against HP Inc. (HPQ) and Hewlett-Packard Development Company, L.P. for infringing its trademarks. According to the lawsuit, WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility, and facilitating paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. These services are offered under WEX's well-known and distinctive WEX family of trademarks. On March 7, 2024, HP announced the launch of its own "WEX," a misappropriation of WEX's trademarks. Like WEX's platform offerings, HP's "WEX" is a platform that aims to supply businesses with innovative solutions to their everyday workforce problems. HP's "WEX" is marketing to a similar customer base as WEX, which is inevitably causing confusion in the marketplace. Both WEX and HP's "WEX" are promoting their respective software as being customer-driven, providing data, assisting in fleet management, increasing productivity, utilizing AI, and reducing friction. WEX has been using the name WEX since 1989 and formally rebranded to WEX in 2012. It holds several federally registered trademarks for WEX, covering software-as-a-service. WEX holds five incontestable trademark registrations protecting use of the WEX name for services that HP's "WEX" is attempting to mirror, claiming services in the same classes as the registered WEX trademarks. WEX tried to resolve this dispute amicably, but HP refused to stop its use of the WEX name. WEX was therefore forced to file this lawsuit. WEX intends to seek a preliminary injunction to force HP to immediately discontinue all further infringement of the WEX trademark.

11:01 EDT H.B. Fuller increases quarterly dividend by 8.5% to 22.25c per share - H.B. Fuller announced that its board of directors approved an increase in the company's regular quarterly cash dividend from 20.5c per share of common stock to 22.25c per share of common stock, payable on May 9 to shareholders of record at the close of business on April 25. This represents an 8.5% increase over the prior quarterly dividend and marks the 55th consecutive year in which the company has increased its dividend, the company stated.

10:24 EDT Lottery.com regains full Nasdaq compliance - Lottery.com has received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market stating that the Company has maintained a minimum market value of publicly held shares of $5,000,000 or greater for the last ten consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(b)(1)(C) and the matter is now closed. Regaining full compliance with Nasdaq paves the way for future growth.

10:15 EDT Marvell sees FY25 AI revenue over $1.5B, FY26 AI revenue over $2.5B - Comments taken from Investor Day presentation slides.

10:00 EDT Walker & Dunlop falls -3.8% - Walker & Dunlop is down -3.8%, or -$3.56 to $89.08.

10:00 EDT Globe Life falls -14.9% - Globe Life is down -14.9%, or -$15.62 to $89.31.

10:00 EDT Hamilton Insurance rises 6.0% - Hamilton Insurance is up 6.0%, or 75c to $13.19.

09:47 EDT CarMax falls -6.5% - CarMax is down -6.5%, or -$5.18 to $74.11.

09:47 EDT Globe Life falls -7.6% - Globe Life is down -7.6%, or -$7.93 to $97.00.

09:47 EDT Frontline rises 6.5% - Frontline is up 6.5%, or $1.51 to $24.61.

09:36 EDT Jaguar Mining announces passing of director John Ellis - Jaguar Mining is sad to announce the passing of John Ellis, a member of the Company's Board of Directors. Mr. Ellis was appointed to the Board on June 24, 2016, and served on Jaguar's Corporate Governance & Compensation Committee and Safety, Environmental, Technical and Reserves Committee.

09:35 EDT FibroBiologics granted Australian patent for cartilage-type cell regeneration - FibroBiologics announced the issuance of a patent from the Australian Patent Office covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells. Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine. Cartilage tissue, due to a lack of vascularization, has a limited capacity to heal when damaged, potentially leading to pain, inflammation, and loss of function in the affected joint. FibroBiologics' fibroblast cell-based technology offers a potential solution to regenerate cartilage tissue and restore its function, by using a natural and biocompatible cellular blend that can adapt to the specific needs of the target tissue.

09:30 EDT Rent the Runway trading halted, volatility trading pause

09:19 EDT N2OFF to purse, implement an inset strategy for monetizing proprietary tech - N2OFF and its subsidiary NTWO OFF LTD announced it intends to pursue and implement an inset strategy aimed at capturing market opportunities with established companies which seek to reduce N2O greenhouse gas emissions. The inset strategy involves collaborating with established companies with Environmental, Social, and Governance initiatives. The Company intends to offer its future product particularly to companies that are focusing on reducing greenhouse emissions in agriculture. "While N2OFF's technology is still in development, the Company is hopeful about its potential, said David Palach, Chief Executive Officer of N2OFF, Inc. "We are excited to initiate an inset strategy, enabling us to approach the market and contribute to emission reduction efforts in agriculture. By partnering with companies committed to sustainability, we believe we have the potential to play a role in reducing N2O emissions."

09:16 EDT Yale launches wireless Yale Keypad - Yale announced the launch of the retrofit Yale Approach Lock with Wi-Fi and the wireless Yale Keypad. Easy to install on the back of most deadbolts, Yale Approach paired with the Yale Keypad is the ultimate do-it-yourself smart lock system for first-time users or renters who typically cannot change their locks. Both products are available for purchase in the U.S. today at ShopYaleHome.com and August.com, with Amazon and additional retail availability to follow.

09:15 EDT MoneyHero hosts Seedly Personal Finance Festival - MoneyHero announced the completion of the Company's seventh annual Seedly Personal Finance Festival. Held this past week on April 6th at the Marina Bay Sands Expo and Convention Center, the 2024 PFF was once again a rousing success, demonstrating the continued growth and influence of the largest event of its kind in Singapore. The annual Festival, which held its first event in 2018, is produced by Seedly, MoneyHero's market-leading platform that builds the largest personal finance community in Singapore. Impressively, the 2024 PFF gathered more than 5,000 attendees, with 70 business, financial, and government leaders speaking, and 35-plus prestigious finance and insurance organizations serving as sponsors. During the event, Seedly also launched a new app - ShopHero by Seedly, the Ultimate Shopping Companion, where users can get instant alerts for discounts, personalise deals and maximise rewards with best-fit credit cards.

09:14 EDT Vox Royalty nominates Shannon McCrae to board of directors - Vox announced that Shannon McCrae will be standing for election to its Board of Directors at the Meeting. Assuming a positive vote of shareholders at the Meeting, Ms. McCrae will join the Board of Directors effective May 30, 2024. Ms. McCrae will fill the vacancy to be created by Pascal Attard, Vox's CFO, who will not be standing for re-election at the Meeting. The other four directors standing for election at the Meeting will be: Kyle Floyd, Rob Sckalor, Alastair McIntyre and Donovan Pollitt. McCrae has recently been involved in mining and exploration through her company, Athena Geoscience and is a Board member of Probe Gold and Atacama Copper.

09:12 EDT MorphoSys board recommends shareholders accept Novartis offer - The Management Board and Supervisory Board of MorphoSys AG (MOR) issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (NVS), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders EUR 68.00 per share in cash, representing a total equity value of EUR 2.7 billion. The offer price corresponds to a premium of 94% and 142% on the volume-weighted average price during the last month and three months, respectively, as of the unaffected January 25, 2024, closing price. Pursuant to Section 27 of the German Securities Acquisition and Takeover Act, the MorphoSys Management Board and Supervisory Board have carefully reviewed the offer document with the support of their financial and legal advisors, accounting for different stakeholder interests as well as potential alternative strategies. The acceptance period has commenced with the publication of the offer document on April 11, 2024, and will end on May 13, 2024, at 24:00 hours CEST and 18:00 hours EDT. MorphoSys and Novartis maintain their expectation that the closing of the Takeover Offer will take place in the first half of 2024. The Takeover Offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital, among other customary closing conditions. All mandatory antitrust approvals for the proposed acquisition have been obtained. MorphoSys and Novartis have agreed to delist MorphoSys shares in Germany and in the U.S. immediately after the public takeover offer has been settled.

09:09 EDT Nanophase Tech announces litigation settlement with BASF - Nanophase Technologies Corporation has agreed to a resolution of all ongoing litigation with BASF. The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days. "We are happy to conclude this litigation on positive terms. BASF has been a good partner to Nanophase over the years, and we expect that partnership to continue to bear fruit in the future," said Nanophase President and CEO Jess Jankowski. "Our commercial teams have remained aligned throughout the litigation process, but I know that all of us are excited and looking forward to focusing all of our energies on enhancing the commercial success of our businesses. Completion of the settlement allows Nanophase and Solesence to focus on what we do best, while continuing to support our sale of mineral-based Active Pharmaceutical Ingredients, into a market that recognizes the benefits these solutions bring. With this behind us, we expect our API and Solesence finished products business to continue to grow, enhanced further by now having the benefit of our undivided attention."

09:08 EDT Edible Garden announces United Natural Foods will carry its new Pulp products - Edible Garden AG (EDBL) announced that United Natural Foods (UNFI) will carry Edible Garden's new line of Pulp sustainable gourmet sauces and chili-based products. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are excited to announce that our sustainable Pulp product line is now available through UNFI Distributors, a leading grocery wholesaler in North America. UNFI serves over 30,000 locations across the continent, including natural product superstores, independent retailers, supermarket chains, e-commerce platforms, and food service providers. The introduction of our Pulp line has received a positive reception from consumers seeking to enhance their meals with its 'Bland to Bold' flavor profile, reinforcing Edible Garden's reputation as 'The Flavor Maker.' We believe that partnering with UNFI, which is committed to fostering a better food system and is at the forefront of meeting consumer demands for healthier food options, perfectly aligns with our Zero-Waste Inspired(R) mission. We are confident that by broadening the availability of our Pulp line through UNFI's network, in addition to our previously announced partnership with KeHE Distributors, we are further accelerating the momentum of the Pulp line, ensuring our unique flavors reach consumers across the United States and Canada."

09:07 EDT Fluence selected by ENGIE to deliver battery-based energy storage project - Fluence Energy, a subsidiary of Fluence Energy, has been selected by ENGIE to deliver a 35 MW / 100 MWh battery-based energy storage project at the Maxima power plant in Lelystad, the Netherlands. The advanced battery energy storage project is located at a site with different types of power generation. It is expected to come into operation in 2025. The project is anticipated to provide critical flexibility to the Dutch electricity system and, through this, increase energy security. Fluence will supply the energy storage technology, software solutions, and services for the project. For Fluence Energy, Inc.'s global operations, this will be another project with ENGIE, following the successful commissioning of the 150 MW / 150 MWh Hazelwood project, Australia's largest-privately funded utility-scale battery, in mid-2023.

09:06 EDT Check Point announces new email security features - Check Point Software announced new email security features that enhance its Check Point Harmony Email & Collaboration portfolio: Patented unified quarantine, DMARC monitoring, archiving, and Smart Banners. Since 2023, Check Point has released over 75 new features for Harmony Email & Collaboration, further strengthening collaborative email security with preventative measures to combat the growing threat of cyber-attacks. The addition of these new features allows for leading protection against advanced threats on a single screen. As part of the Check Point Infinity Platform, Harmony Email & Collaboration features include: Unified Quarantine: This patented feature streamlines email management by allowing administrators and end-users to view and restore all quarantined emails from both Microsoft and Harmony Email through a single, integrated Check Point screen, simplifying the process and reducing administrative effort and redundant friction with end users DMARC Monitoring: Allows organizations to protect their brand reputation and prevent impersonation attacks on their customers and partners by maintaining a strict DMARC policy, without impacting business operations Archiving: Enables the storage of all internal, incoming and outgoing emails for many years, as well as importing archives from competitors, and to support disaster recovery and legal use cases Smart Banners: Educates users on cyber security directly within their emails, promoting policy compliance and enabling precise reporting of suspicious, yet subtly malicious, emails.

09:05 EDT Candel Therapeutics announces U.S. FDA granted ODD to CAN-2409 - Candel Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. "We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. "We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer."

09:04 EDT Apple to expand repair options with support for used genuine parts - Apple announced an upcoming enhancement to existing repair processes that will enable customers and independent repair providers to utilize used Apple parts in repairs. "Beginning with select iPhone models this fall, the new process is designed to maintain an iPhone user's privacy, security, and safety, while offering consumers more options, increasing product longevity, and minimizing the environmental impact of a repair. Used genuine Apple parts will now benefit from the full functionality and security afforded by the original factory calibration, just like new genuine Apple parts," Apple stated. At Apple, we're always looking for new ways to deliver the best possible experience for our customers while reducing the impact we have on the planet, and a key part of that means designing products that last. For the last two years, teams across Apple have been innovating on product design and manufacturing to support repairs with used Apple parts that won't compromise users' safety, security, or privacy. With this latest expansion to our repair program, we're excited to be adding even more choice and convenience for our customers, while helping to extend the life of our products and their parts," added John Ternus, Apple's senior vice president of Hardware Engineering. Reference Link

09:02 EDT Transocean announces proposed private offering of senior notes - Transocean announced that Transocean Inc. commenced a private offering of $1,500,000,000 aggregate principal amount of Senior Notes due 2029 and Senior Notes due 2031 to eligible purchasers pursuant to Rule 144A/Regulation S. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Transocean Ltd. and certain of the Company's subsidiaries. The timing of pricing and terms of the Notes are subject to market conditions and other factors. The Company intends to use a portion of the net proceeds from the offering to fund the offer to purchase for cash any and all of the Company's outstanding 11.50% Senior Guaranteed Notes due 2027 and 7.25% Senior Notes due 2025 and to pay any related premiums and expenses or to redeem any Tender Notes not purchased in the Tender Offers. The Company intends to use the remaining net proceeds from the offering for the redemption of other priority guaranteed notes. Contemporaneously with the offering of the Notes and the Tender Offers, the Company has issued a conditional notice of redemption pursuant to the indenture governing the 2025 Priority Guaranteed Notes to redeem all of the 2025 Priority Guaranteed Notes that remain outstanding following the consummation of the Tender Offers/ The Redemption is scheduled to occur on April 23, 2024, subject to the completion of the offering. The redemption price for the Tender Notes will be equal to 100.00% of the principal amount of such notes to be redeemed, plus accrued and unpaid interest thereon to, but not including, the date of redemption.

09:02 EDT First Horizon: Tracy Bell named CIO of First Horizon Advisors - First Horizon is pleased to announce that Tracy Bell has been promoted to the Chief Investment Officer of First Horizon Advisors, the Wealth Management subsidiary of First Horizon. In this role, Bell will lead the First Horizon Advisors investment team in addition to the bank's Women & Wealth client initiative. Bell brings 27 years of investment management experience from various institutions including Regions, Sterne Agee Asset Management, and IBERIABANK prior to joining First Horizon Advisors as Director of Equity Strategies in 2020.

08:59 EDT MorphoSys Management, Supervisory board recommend Novartis takeover - The Management Board and Supervisory Board of MorphoSys (MOR) issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis (NVS), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders EUR 68.00 per share in cash, representing a total equity value of EUR 2.7B. The offer price corresponds to a premium of 94% and 142% on the volume-weighted average price during the last month and three months, respectively, as of the unaffected January 25 closing price. Pursuant to Section 27 of the German Securities Acquisition and Takeover Act, the MorphoSys Management Board and Supervisory Board have reviewed the offer document with the support of their financial and legal advisors, accounting for different stakeholder interests as well as potential alternative strategies. The acceptance period has commenced with the publication of the offer document on April 11 and will end on May 13. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital, among other customary closing conditions. All mandatory antitrust approvals for the proposed acquisition have been obtained. MorphoSys and Novartis have agreed to delist MorphoSys shares in Germany and in the U.S. immediately after the public takeover offer has been settled.

08:50 EDT Lumen awarded $73.6M contract with U.S. Government Accountability Office - Lumen landed a $73,616,904 contract to transform the U.S. Government Accountability Office's network, data, voice and video connectivity. These technologies powered by Lumen enable GAO to provide Congress, the executive branch and the public with analysis and recommendations that can improve government and save taxpayers billions of dollars. Lumen is delivering secure managed network services, virtual private network services, ethernet transport services, internet protocol services, videoconferencing services, and voice and toll-free services to GAO, which serves as the audit, evaluation and investigative arm of Congress. This task order has a base performance period of one year, with eight additional one-year options.

08:41 EDT Teva announces AJOVY study met all critical efficacy endpoints in China trial - Teva Pharmaceuticals announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients. In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo. All key secondary endpoints were also met including measures for early onset of efficacy during the first month, responder rate analysis defined as 50% reduction of migraine days and reduction of acute headache medication use over 3 months after first use. Study data also show AJOVY was safe and well tolerated with no emerging safety signals. This data is consistent with the previous Phase 3 data for AJOVY which was approved for the preventive treatment of migraine in adults in the U.S. in 2018 and in the EU in 2019. "For the many millions of migraine patients in China,1 there is a need for preventive treatment options that may help reduce the number of migraine days they experience and support the alleviation of the incapacitating symptoms migraine can cause," said Shengyuan Yu, MD, PhD...In the study, AJOVY was safe and well tolerated with no safety signals observed. The most common treatment-related AEs were injection site reactions. Additional findings from this study are planned for presentation at a medical meeting later this year.

08:37 EDT Intelligent Bio Solutions subsidiary broadens IP portfolio - Intelligent Bio Solutions announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus Cartridge Reader. This latest achievement follows the successful protection of the same technology in the United Kingdom and marks another significant milestone in the Company's expansion and protection of its intellectual property. Harry Simeonidis, President and CEO at Intelligent Bio Solutions, commented, "The grant of the European patent is a testament to the ingenuity and hard work of our team. It fortifies our intellectual property portfolio and paves the way for our expansion into the European market. We are excited about the prospects of bringing our innovative technology to more organizations and contributing to safer and healthier workplaces across Europe."

08:36 EDT Silynxcom won first order for its In-Ear Headset system - Silynxcom announced the first order for its In-Ear Headset system. This marks a significant milestone for the Company, positioning Silynxcom at the forefront of the high-tech advanced tactical communication market and signaling strong potential for future growth and profitability. The new In-Ear Headset system designed to meet the unique requirements of law enforcement and public safety organizations, represents a major innovation in secure and encrypted communication. The system is comestible with "Project 25" and "TETRA" communication systems, widely used across the globe. This first order, announced on March 14, 2024, following rigorous testing by a European law enforcement agency, underscores the product's high quality and its ability to meet the high standards demanded by the industry.

08:35 EDT Baxter announces continued expansion of its pharmaceuticals portfolio - Baxter International announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. "These launches demonstrate Baxter's focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications," said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter. "We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market." Product launches within Baxter's Pharmaceuticals portfolio in the U.S. include the following....Ready-to-use formats of standard concentrations of commonly prescribed drugs may offer operational efficiencies for healthcare providers. Compounding a drug for patient use is a multi-step, manual process that requires oversight by pharmacy staff. A ready-to-use product can simplify the preparation process and support patient safety by reducing the chance of contamination2 and avoiding potential errors that may occur when medications are compounded. These newly launched products are now available for use in the U.S

08:34 EDT Bridgeline Digital announces completion of SOC 2 Type II audit - Bridgeline Digital announced the completion of its System and Organization Controls 2 Type II audit, securing a larger total addressable market including enterprises in highly regulated industries. The completion of the audit underscores Bridgeline's commitment to security and to delivering high-quality services to its clients by demonstrating that they have the necessary internal controls and processes in place. The audit included assessment of controls as they related to security, availability, processing integrity, confidentiality and privacy of systems. The audit provides validation that Bridgeline's information security practices meet industry standards stipulated by the American Institute of Certified Public Accountants

08:33 EDT Global Mofy Metaverse adopts OpenUSD as digital asset development standard - Global Mofy Metaverse announced its strategic decision to officially adopt OpenUSD as the standard for digital asset development. The adoption and utilization of this open and dynamic ecosystem for describing, composing, simulating, and collaborating within 3D environments is endorsed by industry leaders worldwide, including NVIDIA, Meta, Autodesk, and others. This strategic transition to OpenUSD is expected to significantly enhance operational efficiencies and open new revenue streams, positioning the Company for increased profitability in the evolving digital marketplace. Universal Scene Description offers numerous advantages across various industries engaged in 3D digital asset creation, including licensing, digital entertainment, the metaverse, and visual effects production. Initially created by Pixar Animation Studio, OpenUSD expedites workflows, team collaborations, and project development by enhancing interoperability across various content tools, data formats, workflows, and platforms. It is utilized for crafting digital assets and environments, particularly for the creation of large-scale, AI-enabled virtual worlds, or for developing the tools necessary to bring these innovative worlds into existence.

08:32 EDT Fiverr announces board authorization of $100M share repurchase program - Fiverr International announced that on April 1, 2024, its Board of Directors has authorized a share repurchase program, under which the company may repurchase up to $100 million of its ordinary shares. "We are pleased to announce the authorization of our first-ever stock repurchase program. This program reflects our confidence in the long-term opportunity for Fiverr and our commitment to creating shareholder value," said Ofer Katz, Fiverr's President and CFO. "We have built a healthy balance sheet enabling us to continue to invest in our strategic initiatives while also returning capital to shareholders. We believe that our current stock price represents an attractive opportunity for a repurchase."

08:31 EDT Blink Charging selected by Keystone Purchasing Network to provide EV charging - Blink Charging announced the Company has been selected by Keystone Purchasing Network as its exclusive provider of EV charging services. The cooperative purchasing program, known as KPN, was established to harness public sector demand for essential products. By actively soliciting sealed competitive bids, it aims to save valuable time and resources for school districts and other public agencies. This program operates under the Central Susquehanna Intermediate Unit, a Pennsylvania educational service agency. "At Blink, we're committed to serving the education sector," said Jim Nemec, Chief Revenue Officer at Blink Charging. "We're particularly proud of our work with schools around the country - working alongside them to educate, understand, and road map out their specific EV goals while leveraging their access to us via this contract. It's gratifying to work closely with our nation's education system to provide charging solutions and, in many cases, an introduction to the EV driving experience for the next generation of Americans."

08:29 EDT Maris-Tech to showcase its solutions at Special Operations Forces weeks - Maris-Tech announced its participation in the upcoming Special Operations Forces Week, which will take place from May 6 to May 9, 2024,in Tampa, Florida. The Company will demonstrate the capabilities of its innovative solutions with AI acceleration capabilities suitable for professional and tactical operations. "Maris-Tech's participation at SOF Week, a highly regarded conference, is part of our efforts to penetrate the U.S. defense industry while focusing on special operations forces and diverse defense platforms, such as unmanned vehicles and other autonomous remote platforms," said Israel Bar, Chief Executive Officer of Maris-Tech.

08:27 EDT Brera Holdings says Alessandro Aleotti resigns from all positions - Brera Holdings announces that Alessandro Aleotti has resigned from all his positions with the Company effective as of April 4, 2024, to pursue philanthropic endeavors. Aleotti founded Brera FC in 2000 and was president until 2022 when acquired by Brera Holdings, the Company's first football club acquisition. Aleotti served as a director and the Chief Strategy Officer of Brera Holdings since July 2022. On February 29, 2024, Aleotti sold approximately 90% of his Brera Holdings' shares to Daniel McClory.

08:25 EDT NKGen Biotech secures additional financing of $5M - NKGen Biotech announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date. Outstanding or issuable securities that may deliver additional cash to the company over time, or on large share and volume moves, after their pending issue and/or registration, include over two million forward purchase shares and our expectation of over ten million warrants with a cash strike price set, or expected to be reset, at $2.00 per share. "This $5 million in funding is a statement of confidence and support for NKGen, our team, and our story in a challenging market. This provides breathing room for us to execute our plans, continue to pursue larger funding opportunities with both financial and strategic investors, and capitalize on our outstanding structured securities upon registration of the underlying shares. It will help fund our clinical trials and operations, filing of our annual report on Form 10-K, and filing of an amended registration statement on Form S-1 soon thereafter. This will help us to achieve additional value-creating milestones across both our neurodegenerative and oncology clinical programs and repay certain bridge funding liabilities," said Paul Song, MD, Chairman and Chief Executive Officer of NKGen Biotech.

08:23 EDT VERB's MARKET.live x TikTok Shop partnership event set for April 25 - Verb Technology Company announced an upcoming special celebratory event in collaboration with TikTok Shop that promises to bring together the Who's Who of livestream shopping at MARKET.live's Studios in Los Alamitos. Set against the backdrop of innovation and collaboration, this event marks the beginning of the exciting partnership between MARKET.live and TikTok Shop aimed at revolutionizing the way consumers engage with their favorite brands. Anticipation is high as over 350 attendees, including prominent industry figures, influencers, and brands, are expected to converge at this groundbreaking event. With more than 150 TikTok affiliates already confirmed, the event promises to be a vibrant gathering of individuals passionate about the future of social commerce.

08:21 EDT Zscaler enters agreement to acquire Airgap Networks, terms not disclosed - Zscaler has signed an agreement to acquire Airgap Networks. Combining Zscaler's Zero Trust SD-WAN and Airgap Networks' agentless segmentation technology will transform how enterprises implement Zero Trust Segmentation to IoT/OT devices, and critical infrastructure across branches, campuses, factories, and data centers, including east-west connectivity. Traditional NAC and network-based firewalls that use static Access Control Lists to control east-west traffic were not designed to prevent sophisticated threats from moving laterally within a Local Area Network. Airgap Networks' novel approach, using an intelligent Dynamic Host Configuration Protocol proxy architecture, isolates every device and dynamically controls access based on identity and context, reducing business risk for enterprises with critical infrastructure. Customers will benefit in the following ways: Extending Zero Trust to Devices on Internal Networks - Airgap Networks' technology enforces Zero Trust principles across east-west device traffic, shrinking the internal attack surface to help eliminate lateral threat movement on campus and OT networks. Securing Critical OT Infrastructure - Airgap Networks' technology delivers real-time device discovery and inline enforcement. It acts as a ransomware kill switch, disabling non-essential device communications to halt lateral threat movement without interrupting business operations. Airgap Networks' solution neutralizes advanced threats, such as ransomware on IoT devices, OT systems, and agent-incapable devices. Delivering Operational Simplicity and Cost Savings - Airgap Networks' solution eliminates the need for risk-prone east-west firewalls and antiquated security technologies, such as Network Access Control with the ability to identify and control all traffic from managed and unmanaged devices on any branch, campus or factory network without requiring changes to the existing switching and routing infrastructure. This dramatically improves enterprises' security posture as traditional approaches using NAC fundamentally contradict the foundational principle of Zero Trust - "never trust, always verify." The terms of the deal were not disclosed.

08:20 EDT Collegium Pharmaceutical announces redemption of convertible senior notes - Collegium Pharmaceutical has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 for redemption on Friday, June 14, 2024. The redemption price will be payable in cash and equal to 100% of the principal amount of each Note called for redemption, plus accrued and unpaid interest on each such Note to, but excluding, the Redemption Date. For each $1,000 principal amount of Notes, the Redemption Price is equal to approximately $1,008.68. The Company's redemption right in respect of the Notes arises pursuant to Section 4.03(B) of the indenture governing the Notes as a result of the last reported sale price of the Company's common stock exceeding 130% of the conversion price of the Notes during the required period of time. Payment of the Redemption Price will be made upon presentation and surrender of the Notes to The Bank of New York Mellon Trust Company, N.A., in its capacity as paying agent under the Indenture at the following address: The Bank of New York Mellon Trust Company, N.A., 2001 Bryan Street, 10th Floor, Dallas, Texas 75201, Attention: Transfers/Redemption/Payments. Notes held through The Depository Trust Company should be presented and surrendered for redemption in accordance with DTC's policies and procedures therefor.

08:18 EDT SciSparc enters merger agreement with AutoMax Motors - SciSparc signed a merger agreement with AutoMax Motors, a vehicle importer company in Israel. According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax. Following the Acquisition, it is contemplated that SciSparc shareholders will hold together approximately 50.01% of the share capital of the post-closing combined company. The Acquisition follows the Company's announcement in June 2022, in which the Company's board of directors resolved to review potential strategic transactions to maximize shareholder value. The Company's ongoing business operations, including its late-stage pharmaceutical segment, will continue to operate. As a result of the Acquisition, all outstanding shares of AutoMax will be converted into the right to receive ordinary shares of SciSparc. Following the closing, it is contemplated that AutoMax's equity holders will hold together approximately 49.99%, subject to adjustments, of the Combined Company's share capital. At the closing of the Acquisition, SciSparc has committed to hold at least $4.25 million in net cash. The Acquisition is subject to various approvals, including compliance with any regulatory requirements, including certain Israeli court approvals and SciSparc and AutoMax shareholder approvals. Mr. Amitai Weiss, the chairman of SciSparc, is also the chairman of AutoMax.

08:15 EDT Black Diamond Therapeutics announces changes to board of directors - Black Diamond Therapeutics announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncology expertise to our board as we advance BDTX-1535, a potential first and best-in-class fourth-generation EGFR inhibitor," said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics. "I would also like to thank Alex for his many years of support for Black Diamond and Wendy for her important contributions as a board member."

08:15 EDT Microchip acquries VSI to extend automotive market leadership - Microchip Technology announces the completed acquisition of Seoul, Korea-based VSI. The terms of the transaction are not disclosed. "This acquisition brings VSI's knowledgeable team, their market traction and ASA Motion Link technologies and products to Microchip's expansive automotive networking portfolio to better serve the ADAS megatrend we are focused on," said Mitch Obolsky, senior vice president of Microchip's automotive products, networking, and data center business units. "As the industry converges around three primary IVN pillars - Ethernet, PCIe and ASA Motion Link, camera and display connectivity is one of the fastest growing and largest IVN markets. With VSI, Microchip can now offer products that span all three pillars and also provide automotive security, microcontrollers, motor control, touch and power management solutions to our customers to enable their next-generation software-defined vehicle architectures."

08:13 EDT Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial - Processa Pharmaceuticals presented two abstracts at the American Association for Cancer Research Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine product. The NGC-Cap Phase 1b trial evaluated ascending doses of capecitabine when combined with a fixed dose of PCS6422 in patients with advanced, relapsed, or refractory progressive gastrointestinal cancer. These patients had to relapse from or fail all other treatments. NGC-Cap demonstrated greater 5-FU exposure and lower fluoro-beta-alanine exposure with a better or similar side effect profile compared with monotherapy capecitabine. The poster presentation, titled "Next generation capecitabine in Phase 1b trial significantly increases 5-FU exposure while improving safety profile compared to capecitabine," reported the following more recent findings: 18 patients were enrolled in the first four dose levels of capecitabine in NGC-Cap; The 5-FU exposure, expressed as the area under the 5-FU plasma concentration curve or AUC, for the two highest doses cohorts of 150 and 225 mg twice-daily NGC-Cap were 4,551 and 6,889 ng-hr/ml, respectively, which is approximately 5-10 times the AUC of 698 previously reported for a larger dose of approximately 2,250 mg twice-daily of monotherapy capecitabine; Similarly, the 5-FU maximum plasma concentrations for these two cohorts were greater at 1.5 times the Cmax of monotherapy capecitabine; As expected, with the greater 5-FU exposure for all the NGC-Cap cohorts, the incidence of anabolite related side effects was also greater than monotherapy treatment, suggesting that more drug was distributed to duplicating cancer cells and normal cells; The extremely low FBAL catabolite formation and exposure across all NGC-Cap doses resulted in the incidence of catabolite related side effects to be less with only one patient having Grade 1 hand-foot-syndrome, an FBAL related side effect often requiring dose modifications. In addition, Processa presented a second abstract at AACR titled "Application of phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principles of Project Optimus." This abstract briefly describes the U.S. Food and Drug Administration's Project Optimus Initiative and draft optimal dosage regimen guidance, which requires an ODR justified by a dose-ranging efficacy and safety study, as opposed to a maximum tolerated dose approach. Processa provided preclinical and Phase 1 oncology study examples to demonstrate how the exposure-response relationships for safety and efficacy can provide the recommended dose range to define and justify the optimal dosage regimen in an efficacy-safety study, in a pivotal study, and for FDA approval. The abstract also noted that Project Optimus may require alterations to the design, analysis, and interpretation of clinical trials for cancer drugs compared with what has been done in the past.

08:11 EDT MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC - MEI Pharma reported that the company's Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionally, the Company's Board of Directors unanimously determined not to proceed with a second return of capital under the October 31 Anson Funds and Cable Car Capital cooperation agreement in order to conserve resources and align strategic investment, and thereby extend the Company's operational runway. "We are very fortunate as a development-stage therapeutics company to have two very promising oncology candidates, voruciclib and ME-344, that continue to generate data supporting their potential as novel therapeutics to benefit patients with cancer. With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources," said David Urso, president and chief executive officer of MEI Pharma..."The entire MEI Board is pleased to unanimously align around a strategy that we believe is in the best interests of the Company's shareholders, with the intent to optimize the opportunity to judiciously advance both of the voruciclib and ME-344 development programs," stated Taheer Datoo, director of MEI Pharma and principal and portfolio manager of Anson Funds. "Under the strategy, use of capital is measured and balanced to achieve key clinical objectives designed to optimize the development potential these product candidates hold to advance the standard of care for patients with cancer while also optimizing the interests of our shareholders."

08:10 EDT Montauk Brewing releases first non-alcoholic brew Montauk N.A. IPA - Montauk Brewing announced the launch of its new Montauk N.A. IPA, a flavorful 'Non-Alcoholic' brew that's thankfully all Montauk. Tapping into the high-growth non-alcohol category, Montauk's N.A. IPA is meticulously brewed to the same high standards as its alcoholic counterparts, ensuring that every sip delivers a refreshing and flavorful experience. This well-balanced brew achieves perfect harmony, blending the clean bitterness of hops with a subtle sweetness. Crafted to meet the increasing demand for full-flavor non-alcoholic beverages, Montauk N.A. IPA is brewed with Citra, Mosaic, and a blend of Cryo hops, offering a fresh aroma of orange and pink grapefruit. Available in six-packs of 12-ounce cans with less than 0.5% ABV, it is incredibly delicious for those who want a great-tasting IPA without the alcohol of traditional beers.

08:08 EDT Natera announces publication of dd-cfDNA study data - Natera announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA, or dd-cfDNA, test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled at 54 participating transplant centers. This published study included 1,631 patients with =18 months of follow-up data. Key findings include: dd-cfDNA levels were significantly elevated up to five months before biopsy-proven antibody-mediated acute rejection, or ABMR, and up to two months before biopsy-proven T cell-mediated rejection, or TCMR, compared to patients with a non-rejection biopsy. In contrast, serum creatinine levels were not significantly elevated at any time point before biopsy-proven TCMR or ABMR. Multiple increased dd-cfDNA results were associated with lower eGFR, high immunological risk factors, and suspected ABMR in the absence of rejection on biopsy. These data further support the Prospera Kidney test's value as an early indicator of rejection vs biopsy. Real-world performance of the Prospera Kidney test to detect all forms of rejection in 249 patients with matched biopsy demonstrated an area under the curve of 0.88, showcasing performance consistent with prior validations.

08:07 EDT Harmony Biosciences signs exclusive licensing agreement for sleeping disorders - Harmony Biosciences signed an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. The agreement will accelerate the development of this orexin-2 receptor agonist. Harmony will pay Bioprojet an upfront license fee of $25.5M for the exclusive right to develop, manufacture and commercialize TPM-1116 in the U.S. and Latin American territories. In addition, Harmony is obligated to pay up to $127.5M upon achievement of development and regulatory milestones and up to $240M upon achievement of sales-based milestones. Finally, Harmony will pay a royalty rate in the mid-teens on sales of product in the licensed territories.

08:06 EDT ABM initiates EPC program for Clarke County Commission - ABM announced the initiation of an Energy Performance Contracting program for the Clarke County Commission in Alabama. The project includes upgrades to HVAC systems, lighting technology, and related controls that are expected to create $1.8 million in cost savings over 20 years and will also improve security and indoor air quality for the county's facilities.

08:06 EDT Boundless Bio doses first patient in BBI-825 trial - Boundless Bio announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications. ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells. BBI-825, the company's second ecDNA-directed therapy to enter clinical trials, is a novel, selective, oral small molecule inhibitor of ribonucleotide reductase, a rate-limiting enzyme responsible for the de novo synthesis of deoxyribonucleotides, the building blocks of DNA. Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.

08:05 EDT Genetic Technologies to pilot GeneType in Breast Screen centers across U.S. - Genetic Technologies announces the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented. It will be a significant step forward in personalised medicine, particularly in the context of breast density notification and supplemental screening options for those women at increased risk. This pioneering study stems from feedback from prominent employer and payor groups in the United States, that recognise women's healthcare, particularly around breast cancer, contains the most promising health and economic benefits.

08:04 EDT Enliven announces proof of concept data from Phase 1 trial of ELVN-001 - Enliven Therapeutics announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors. Preliminary Efficacy: ELVN-001 achieved a cumulative major molecular response rate of 44% by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and/or who were TKI-resistant: Among post-asciminib patients, ELVN-001 achieved a cumulative MMR rate of 44% by 12 weeks. Among TKI-resistant patients, ELVN-001 achieved a cumulative MMR rate of 40% by 12 weeks. Among response-evaluable patients, all had improved or stable BCR::ABL1 transcript levels by 12 weeks. These data compare favorably to precedent Phase 1 cumulative MMR rates for approved BCR::ABL1 TKIs, particularly given the shorter time frame for response assessment and a more heavily pre-treated patient population. Preliminary Safety: ELVN-001 has been well tolerated, consistent with its selective kinase profile. A maximum tolerated dose has not been identified, and there have been no dose reductions. No greater than or equal to Grade 3 non-hematologic treatment-related adverse events and no specific non-hematologic TRAE of any grade occurred in greater than11% of patients. Hematologic adverse events observed are consistent with the approved BCR::ABL1 TKIs. Pharmacokinetics & Target Coverage: ELVN-001's PK profile supports once daily dosing with flexible administration requirements. Importantly, given the strong correlation between target coverage and 1L efficacy for the approved BCR::ABL1 TKIs, ELVN-001, at doses equal to or greater than 40mg QD, achieved superior target coverage compared to 2nd Generation, active-site TKIs.

08:03 EDT NV5 Global awarded $13M in data center mission critical contracts - NV5 Global has been awarded $13 million in contracts to support the expansion of data center assets for technology and financial companies in Asia and the United States.

08:01 EDT Orezone Gold reports Q1 gold production 30,139 ounces - Orezone Gold announced its first quarter 2024 gold production results from its Bombore Gold Mine, located in Burkina Faso: Gold production of 30,139oz; Gold sales of 31,229oz at an average realized price of US$2,066/oz, resulting in sales of $64.5 million. Patrick Downey, President & CEO stated, "Q1 marked a solid start to 2024. Production to date for Q2 is trending above plan and the Company remains well positioned to meet its 2024 production guidance of 110,000 - 125,000oz."

07:59 EDT HPQ Silicon announces reworking of HPQ Fumed Silica Reactor Pilot Plant design - HPQ Silicon updates shareholders on its HPQ Fumed Silica Reactor technology pathway to commercialization. HPQ Silicon's subsidiary, HPQ Silica Polvere, shared that its technology provider and equipment supplier, PyroGenesis Canada responsible for the Fumed Silica project, has reworked and simplified the overall design of the 50 tonnes per year pilot plant system. This rework is set to accelerate the process to commercial scalability, effectively minimizing the risks associated with scaling up. Furthermore, it streamlines the process of constructing HPQ Polvere's inaugural 1,000 TPY commercial-scale plant, ensuring a smoother path to production. Importantly, this rework will not impact the scheduled commissioning of the pilot plant in Q2 2024.

07:52 EDT Constellation Brands sees $3B in capex for additions in Mexico facilities - The company had approximately 48 million hectoliters of capacity across its existing facilities in Mexico at the end of fiscal 2024. From fiscal 2025 to fiscal 2028, the company expects approximately $3 billion of capital expenditures to continue the development of modular additions at existing facilities in Mexico and its third brewery site at Veracruz.

07:45 EDT Constellation Brands CEO 'confident' about growth trajectory of Beer portfolio - CEO Bill Newlands said, "We delivered another year of solid performance in Fiscal 24. Our Beer Business continued its strong growth momentum as it achieved its 56th consecutive quarter of volume growth while maintaining best-in-class margins. These results were driven by sustained growth of our industry-leading beer brands that continue to gain share. As we head into Fiscal 25, we remain confident about the growth trajectory of our Beer portfolio. We continue to see growth potential in our Wine and Spirits business as we focus on strong commercial and operational execution."

07:35 EDT Executive officers of Zai Lab 'do not anticipate selling any shares' in 2024 - The Executive Officers of Zai Lab Limited , Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards

07:34 EDT Marimed closes acquisition of Thrive Dispensary in Casey, Illinois - MariMed announced the closing of its acquisition of Allgreens Dispensary on April 9, 2024. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows MariMed to fully consolidate the financial results of the Company's Thrive-branded dispensary in Casey, Illinois, which had previously been operated under a Managed Services Agreement. Thrive Casey is the only dispensary in Clark County, Illinois, 30 miles west of Terre Haute, Indiana. The Company continues to look for additional retail locations in Illinois, where adult-use cannabis sales exceeded $1.6 billion last year.

07:33 EDT Soligenix confirms FDA orphan designation for active ingredient in SuVax - Soligenix announced that the Office of Orphan Products Development of the United States FDA has granted orphan drug designation to the active ingredient in SuVax, the subunit protein vaccine of recombinantly expressed Sudan ebolavirus glycoprotein, for "the prevention and post-exposure prophylaxis against SUDV infection."

07:32 EDT Indaptus presents mechanism of action data at AACR for Decoy platform - Indaptus Therapeutics unveiled its poster at the 2024 Annual Meeting of the American Association for Cancer Research, AACR, in San Diego on Wednesday, April 10th. The poster details mechanism of action data that demonstrates the Company's Decoy platform successfully induces, matures or activates multiple immune cell types involved in anti-tumor responses. The latest findings significantly enhance the Company's understanding of its "Decoy" platform technology, which uses killed, non-pathogenic bacteria engineered to activate the immune system to attack tumors. The study highlights the platform's effectiveness in engaging key innate and adaptive immune cells, including, natural killer cells, natural killer T cells, dendritic cells, CD4+, and CD8+ T cells. In some settings, the platform also produced additive or synergistic activity in combination with IL-2, an approved cancer drug. Additionally, the data reveal that the Decoy platform may not only boost the immune system's ability to recognize and kill tumor cells, but potentially also overcome a mechanism that suppresses the immune response. The results suggest that the Company's Decoy bacteria can both directly and indirectly prime the immune system to more effectively fight cancer.

07:25 EDT Alta Global to reestablish Mixedmartialarts.com - Alta Global Group announced an update on its recent acquisition of 'The Underground' and mixedmartialarts.com, which will become a core pillar of Alta's strategy to connect with MMA fans and grow combat sports participation globally. The acquisition of 'The Underground' and mixedmartialarts.com offers Alta Global Group several key advantages that reinforce its position as a premier destination for martial arts and combat sports training: 1. Accelerated Growth: Leveraging mixedmartialarts.com brings significant reach with; A combined user base of 530,000, over 9,000 published athlete profiles, 5 million social media followers, and 15 million monthly views, Providing Alta Global Group the opportunity for exponential growth in the industry. 2. Access to a Premier Platform: By acquiring mixedmartialarts.com, Alta Global Group gains access to a very highly regarded online platform with a rich history dating back to 1998. This acquisition presents exciting opportunities to engage audiences in support of growing the sport of MMA. 3. Strategic Expansion: This partnership enables Alta Global Group to strengthen its online presence in the martial arts and combat sports community across key markets, including the US, Europe, Asia, Central and South America, and the Middle East.

07:14 EDT Ivanhoe Electric, Ma'aden complete first quarter of exploration activities - Ivanhoe Electric provided an update following the completion of the first full quarter of exploration activities in Saudi Arabia by our 50/50-owned joint venture company established between Ivanhoe Electric and Saudi Arabian Mining Company Ma'aden. Ivanhoe Electric's President and CEO Taylor Melvin commented: "We had an exceptional first quarter of exploration activities in Saudi Arabia with our partners at Ma'aden. Our dedicated joint team completed the first Typhoon survey at Umm Ash Shalahib and identified our first drill targets which we expect to start drilling by the end of May. We demonstrated the disruptive capabilities of Typhoon together with the machine learning-based inversion software of our subsidiary, Computational Geosciences, to rapidly identify subsurface geophysical anomalies in a challenging geologic environment. With large areas of resistive rock exposed at surface, several portions of our survey required transmission voltages of over 5,000 volts, which Typhoon is capable of achieving while maintaining a high signal quality. We are excited to continue our Joint Venture's exploration activities across the Al Amar and Wadi Bidah belts as we deploy a new generation of Typhoon units into the field."

07:11 EDT Codexis appoints Carole Cobb to strategic advisory board - Codexis announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board. Ms. Cobb is the former COO at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications.

07:10 EDT SolarEdge announces compliance with UK PSTI regulation - SolarEdge announced that its entire product portfolio complies with the UK's Product Security and Telecommunications Infrastructure, or PSTI, regulation, due to come into effect on April 29, 2024.

07:09 EDT Century Therapeutics announces strategic pipeline expansion - Century Therapeutics announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies as well as a planned clinical trial in systemic lupus erythematosus, which is on track to be initiated in the first half of 2024. Century plans to pursue additional autoimmune disease indication regulatory filings in 2024. Century plans to pursue additional autoimmune disease indication regulatory filings in 2024. Century's increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors. Concurrently, Century announced pipeline and platform enhancements through the acquisition of Clade Therapeutics. "Today's news signifies a transformative milestone for Century, as we accelerate and broaden our research and development initiatives in autoimmune diseases and iPSC-derived cell therapy on a larger scale. With support from a distinguished group of investors, coupled with the acquisition of Clade, we are poised for continued success," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century. "We believe this strategic expansion of CNTY-101 into additional autoimmune disease indications, coupled with the incorporation of multiple new next-generation assets into our pipeline, represents an important step forward in our goal to address significant unmet need for patients across these serious diseases. We look forward to initiating CALiPSO-1 in SLE in the first half of this year, as well as the near-term pursuit of additional regulatory filings in autoimmune disease for CNTY-101, and presenting additional clinical data from ELiPSE-1 trial in the middle of this year."

07:07 EDT Athira Pharma announces publication of preclinical data on fosgonimeton - Athira Pharma announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer's disease. The original research article, "Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer's Disease," authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics. "These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer's disease targeting multiple facets of its complex pathophysiology," said Kevin Church, Ph.D., Chief Scientific Officer of Athira. "By positively modulating the HGF signaling system, fosgonimeton demonstrated neuroprotective and neurotrophic effects, countering mechanisms of amyloid-beta (Abeta)-induced toxicity both in vitro and in vivo. Our preclinical findings describe several mechanisms by which fosgonimeton may disrupt the neurodegenerative cascade of Alzheimer's disease downstream of Abeta toxicity, including reduction of mitochondrial oxidative stress and excitotoxicity, improvement of autophagic pathway function, and attenuation of tau hyperphosphorylation."

07:07 EDT H&E Equipment signs definitive agreement to acquire Lewistown Rental - H&E Equipment Services announced the signing of a definitive agreement to acquire Lewistown Rental, a Lewistown, Montana-based equipment rental business and three of its affiliated rental operations in Havre, Glasgow and Great Falls, Montana. Each location serves multiple end markets, including non-residential, industrial and agriculture. The company and its affiliates deploy a diverse fleet of equipment with a total estimated fleet value, as measured by original equipment cost of $28.5M . The transaction is expected to close in the second quarter of 2024, following the satisfaction of customary closing conditions. Brad Barber, chief executive officer of H&E, stated, "Lewistown Rental, together with its affiliated operations, has demonstrated impressive growth over the past several years by addressing a unique customer base across underserved markets in northern and central Montana, utilizing a diverse and comprehensive mix of equipment. Growth prospects in this region and across the state of Montana continue to improve, with rising demand in non-residential construction, including commercial and infrastructure projects, industrial activities and agricultural production. The transaction is expected to complement our existing branch locations in the cities of Billings and Belgrade." Following the close of the transaction, H&E's equipment rental operations will extend across 145 locations in 30 states.

07:06 EDT Enthusiast Gaming's Luminosity partners with Kroger for Luminosity Invitational - Enthusiast Gaming Holdings' Luminosity Gaming will be hosting a live in-person Super Smash Bros Ultimate invitational event in partnership with Kroger and Blackhawk Network. The one-day event will be hosted in Miami, Florida, at the ROK Esports Center on April 20th, 2024, and will feature ten of the top competitors in Super Smash Bros Ultimate, including Luminosity's own Leonardo 'MkLeo' Perez, Enrique 'Maister' Hernandez, Gavin 'Tweek' Dempsey, and Carlos 'Sonix' Perez, and professional players from other top esports teams such as Team Liquid and Moist Esports. The event will be commentated by Luminosity content creators Maximillian 'MaxKetchum' Krchmar and Phillip 'EE' Stewart, and live streamed directly on Luminosity Gaming's Twitch and YouTube channels.

07:05 EDT Arvinas enters exclusive strategic license agreement with Novartis for ARV-766 - Arvinas (ARVN) announced it has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen receptor degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis. Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialization of ARV-766 and will have all research, development, manufacturing, and commercialization rights with respect to the preclinical AR-V7 program. Arvinas will receive an upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.

07:05 EDT CarMax falls 7% to $73.50 after Q4 results miss estimates

07:04 EDT Eliem Therapeutics enters agreement to acquire Tenet Medicines - Eliem Therapeutics and Tenet Medicines announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy. In support of the acquisition, Eliem has entered into a securities purchase agreement for a $120 million private placement of common stock with a syndicate of new and existing institutional life science investors including RA Capital Management, Deep Track Capital, Boxer Capital, Janus Henderson Investors, Pontifax and Samsara Biocapital. The private placement is expected to close concurrently with the closing of the acquisition. Immediately following the closing of the acquisition and the private placement, the total cash and cash equivalents of the combined company are expected to be approximately $210 million. Eliem expects this will be sufficient to fund the combined company's planned operations into 2027 and to enable the potential attainment of key clinical and development milestones for TNT119. The acquisition and private placement are expected to close in the middle of 2024, subject to approval by Eliem's stockholders and other customary closing conditions. Tenet's lead product candidate, TNT119, is an anti-CD19 antibody with potential best-in class properties designed to achieve broad and deep depletion of pathogenic B-cells with a favorable tolerability profile and convenient dosing regimen with the potential for subcutaneous administration. After closing of the transaction, the strategy of the combined company will be to develop TNT119 for a range of autoimmune-mediated diseases, where we believe CD19-targeted approaches have clear biological rationale, where the combined company can potentially achieve clinical proof-of-concept, and where the combined company can introduce product candidates that can be meaningfully differentiated in the market. TNT119's lead indication is in systemic lupus erythematosus, the most common type of lupus and an autoimmune disease in which the immune system attacks its own tissue causing widespread inflammation and tissue damage in affected organs including joints, skin, brain, lungs kidneys and blood vessels. In systemic lupus erythematosus, the underlying pathology involves the production of autoantibodies by autoreactive B cells and the formation of immune complexes that contribute to inflammation and tissue damage. CD19 is a protein expressed on the surface of these B cells, and it plays a role in B cell activation, proliferation and survival. TNT119 is designed to target and deplete CD19-expressing B cells known to produce autoantibodies, thereby providing a novel approach to the potential treatment of systemic lupus erythematosus. The combined company expects to initiate Phase 2 clinical trials of TNT119 for the treatment of systemic lupus erythematosus and immune thrombocytopenia in the second half of 2024. Under the terms of the acquisition agreement, Tenet stockholders are entitled to receive shares of Eliem's common stock upon the closing of the acquisition. Pre-acquisition Tenet equityholders are expected to own approximately 15% of the combined company, and pre-acquisition Eliem equityholders are expected to own approximately 85% of the combined company, in each case, before giving effect to the concurrent private placement. The acquisition agreement has been unanimously approved by the boards of directors of both companies, as well as by a special committee of Eliem's board of directors consisting solely of independent and disinterested directors. The acquisition and the private placement are expected to close in the middle of 2024, subject to Eliem stockholder approval and other customary closing conditions. In the private placement, Eliem has agreed to sell 31,238,282 shares of its common stock at a price of $3.84 per share, and upon the closing of the private placement, will receive aggregate gross proceeds of $120 million. Following the closing of the acquisition, the combined company's leadership team will include members of Tenet's current leadership team, including Stephen Thomas, as interim Chief Executive Officer, and William Bonificio, as interim Chief Business Officer. The board of directors of the combined company will be composed of seven board members, consisting of the five existing board members of Eliem, one board member that will be named by Tenet, and Stephen Thomas, the interim Chief Executive Officer.

07:02 EDT Ginkgo Bioworks acquires AgBiome's platform assets, terms not disclosed - Ginkgo Bioworks announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500M unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated into Ginkgo Ag Biologicals Services, established with the acquisition of a Bayer agricultural biologicals R&D facility in 2022, and will expand Ginkgo's proprietary unified metagenomics database. Combined, this creates one of the deepest and most advanced ag biological discovery and development platforms as well as a rich resource for the development of AI models for biological R&D.

06:59 EDT Steris to sell Dental segment to Peak Rock Capital for $787.5M - Steris announced that the company has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital, a leading middle-market private investment firm, for $787.5M. The Transaction is structured as an equity sale. The Transaction terms also include the opportunity for Steris to receive an additional earnout of up to $12.5M, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025. The Dental segment reported revenue of $407 million and contributed segment operating income of $86M in the trailing twelve-month period ended December 31, 2023. The Transaction is subject to customary closing conditions, including regulatory review, and is anticipated to close in the first quarter of fiscal year 2025. STERIS intends to use the proceeds primarily to repay debt. On a full year run rate basis, Steris expects the resulting benefit of the reduction in interest expense to be approximately 35c per diluted share. The Dental segment will be reported as discontinued operations for the fourth quarter and full year of fiscal 2024. The company will provide outlook for fiscal 2025 reflecting this Transaction when fourth quarter fiscal 2024 results are issued.

06:54 EDT The Buckle reports March comparable store net sales down 9.4% vs. last year - Reports net sales for the 5-week fiscal month ended April 6, 2024 down 8.0% to $104.3M from $113.4M for the prior year 5-week fiscal month ended April 1, 2023. Comparable store net sales year-to-date for the 9-week period ended April 6, 2024 decreased 10.3% from comparable store net sales for the 9-week period ended April 8, 2023. Net sales for the 9-week fiscal period ended April 6, 2024 decreased 6.8% to $182.6M vs. $195.9M for the prior year 9-week fiscal period ended April 1, 2023.

06:52 EDT CarMax targets new store growth of five locations in FY25 - "For fiscal 2025, we are planning new store growth of five locations, as well as our second stand-alone reconditioning center and one stand-alone auction facility. We expect capital expenditures between $500 million and $550 million in fiscal year 2025 largely reflecting spending to support our future long-term growth in offsite-reconditioning and auction facilities, as well as our new stores."

06:26 EDT Parsons included on $200M U.S. Army Corps of Engineers construction contract - Parsons was included on a $200M indefinite-delivery, indefinite-quantity multiple award task order contract by the U.S. Army Corps of Engineers Fort Worth District. The construction management services contract has a three-year base period of performance with two, two-year option periods and represents new work for the company. Under this contract, Parsons will compete for task orders to provide supervision, personnel, and administrative and logistics support for USACE Southwestern Division Construction Phase Services on large military construction programs.

06:17 EDT Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay - Roche (RHHBY) announced that its Elecsys pTau217 assay received Breakthrough Device Designation, BDD, from the U.S. Food and Drug Administration, FDA. This blood test, which is being developed in collaboration with Eli Lilly (LLY) and Company, will be used to help identify the presence or absence of amyloid pathology in individuals, which can help ensure they are able to receive appropriate care. "The incidence of dementia is growing worldwide, with 75 percent of cases remaining undiagnosed. Consequently, there is a critical role for Diagnostics to play in addressing this global health challenge," said Matt Sause, CEO of Roche Diagnostics. "We believe pTau217 is going to be crucial in the diagnosis of Alzheimer's disease, a condition where Roche Diagnostics is committed to improving the lives of patients worldwide. We plan to leverage our installed base of diagnostic systems, which is the largest in the world, to ensure we are able to create access to this test for those who need it the most."

06:09 EDT Google Cloud, Home Depot extend multi-year relationship - Google Cloud (GOOGL) and Home Depot (HD) announced an extension of their multi-year relationship. The two companies have collaborated closely since 2015. The extended partnership with Google Cloud announced involves Home Depot accessing Google Cloud's AI capabilities to enhance the customer experience and optimize operations. This includes leveraging technologies like machine learning, computer vision, and generative AI to enhance the retailer's inventory management operations and improve its overall supply chain efficiency. In addition, the business will tap into future e-commerce enhancements to enable greater digital scalability. By harnessing Google Cloud's AI innovation platform, Vertex AI, advanced model training capabilities, and advanced data analytics, Home Depot aims to gain deeper insights into customer preferences and needs.

05:18 EDT Allot Ltd. CFO Ziv Leitman to depart - Allot Ltd. announced that its CFO, Ziv Leitman, is leaving the company to assume the position of CFO at a start up company in a different field of activity. The company has commenced a formal search for a new CFO. To ensure a transition, Leitman will continue in his position through June 30.

05:11 EDT SHL Telemedicine announces results from TELE-ACS Trial - SHL Telemedicine announced the full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL's SmartHeart 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI patients at home. A 76% reduction in the likelihood of hospital readmission within six months for patients using telemedicine. A 41% decrease in the likelihood of attending the emergency department compared to standard care recipients. Significant reductions in unplanned coronary revascularizations. Notable decreases in patient-reported symptoms, including chest pain, breathlessness, and dizziness. The TELE-ACS clinical trial, conducted at a large tertiary center in London, UK, from January 2022 to April 2023, involved 337 participants. It has set a new benchmark in the use of telemedicine for the management of post-ACS patients by reducing hospital readmissions, ED visits, lowering unplanned revascularization rates and improving patient outcomes. The investigator-initiated trial results, led by Ramzi Khamis and Nasser S. Alshahrani, were presented at the American College of Cardiology's 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions in Atlanta. Moreover, the study was also published in the leading Journal of the American College of Cardiology.